Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-303A and AD-3031 in Male Androgenetic Alopecia
NCT07490327Phase 2Not yet recruiting
- Sponsor
- Moogene Medi
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AD-303A in androgenetic alopecia (AGA), sponsored by Moogene Medi. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
AD-303A
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT07490327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07490327.